Taro Yamanaka/X
Apr 21, 2025, 17:04
Taro Yamanaka: DESTINY-Breast09 T-DXd + pertuzumab significantly improved PFS vs. THP in 1L setting
Taro Yamanaka, Medical Oncologist at National Cancer Center Hospital, Japan, shared a post on X:
“Big news for HER2+ MBC!
DESTINY-Breast09 T-DXd + pertuzumab significantly improved PFS vs. THP in 1L setting.
OS data still maturing, but early trends look promising.
Detailed results to follow—future updates will be key.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 07:18
May 11, 2025, 07:13
May 11, 2025, 06:58
May 11, 2025, 06:45
May 10, 2025, 23:57